Padrón-Nieves Maritza, Machuca Claudia, Díaz Emilia, Cotrim Paulo, Rodriguez Noris, Ponte-Sucre Alicia
Laboratorio de Fisiología Molecular, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.
Parasitol Res. 2014 Jun;113(6):2121-8. doi: 10.1007/s00436-014-3862-4. Epub 2014 Mar 27.
Besides infection with drug-resistant parasites, therapeutic failure in leishmaniasis may be caused by altered drug pharmacokinetics, re-infection, and host immunologic compromise. Our aim has been to evaluate if relapses that occur in patients suffering from diffuse cutaneous leishmaniasis (DCL) associate with changes in the fitness of infecting organisms. Therefore, in isolates from patients suffering DCL, we correlated glucose uptake and plasma membrane potential and compared the results with those obtained from reference strains. The data demonstrate that Leishmania parasites causing DCL incorporate glucose at an efficient rate, albeit without significant changes in the plasma membrane potential as their corresponding reference strains. The isolate that did not change its accumulation rate of glucose compared to its reference strain expressed a less polarized membrane potential that was insensitive to mitochondrial inhibitors, suggesting a metabolic dysfunction that may result in glycolysis being the main source of ATP. The results constitute a proof of concept that indicates that parasites causing DCL adapted well to drug pressure and expressed an increased fitness. That is, that in Leishmania mexicana and Leishmania amazonensis, parasites isolated from DCL patients, a strong modification of the parasite physiology might occur. As consequences, the parasites adapted well to drug pressure, increased their fitness, and they had an efficient glucose uptake rate albeit not significant changes in membrane potential as their corresponding reference strains. Further validation of the concepts herein established and whether or not the third isolate corresponds with a drug-resistant phenotype need to be demonstrated at the genetic level.
除了感染耐药寄生虫外,利什曼病治疗失败可能由药物药代动力学改变、再次感染和宿主免疫功能受损引起。我们的目的是评估弥漫性皮肤利什曼病(DCL)患者发生的复发是否与感染生物体适应性的变化有关。因此,在来自DCL患者的分离株中,我们关联了葡萄糖摄取和质膜电位,并将结果与从参考菌株获得的结果进行比较。数据表明,引起DCL的利什曼原虫以高效的速率摄取葡萄糖,尽管其质膜电位与相应的参考菌株相比没有显著变化。与参考菌株相比,葡萄糖积累速率没有变化的分离株表现出极化程度较低的膜电位,对线粒体抑制剂不敏感,这表明可能存在代谢功能障碍,导致糖酵解成为ATP的主要来源。这些结果构成了一个概念验证,表明引起DCL的寄生虫很好地适应了药物压力并表现出适应性增强。也就是说,在墨西哥利什曼原虫和亚马逊利什曼原虫中,从DCL患者分离出的寄生虫可能发生了强烈的生理改变。结果,这些寄生虫很好地适应了药物压力,适应性增强,并且具有高效的葡萄糖摄取率,尽管其膜电位与相应的参考菌株相比没有显著变化。本文所确立概念的进一步验证以及第三个分离株是否与耐药表型相符,需要在基因水平上进行证明。